France's RHODIA (annual turnover of around EUR 250 mil, workforce of 740) has sold it specialist customised organic pharmaceuticals synthesis business to a small Indian company SHASUN for an undisclosed amount. The deal mainly covers the business of a US company, CHIREX, bought in 2000, with two sites in the UK employing 340 people. CHIREX was RHODIA's biggest loss-making subsidiary (EUR 20 mil in the first three quarters of 2005).